Dahake Shweta B, Uke Ashish, Luharia Anurag, Luharia Monika, Mishra Gaurav V, Mahakalkar Chanrashekhar
Medical Physics, Datta Meghe Institute of Higher Education and Research, Wardha, IND.
Radiotherapy, Datta Meghe Institute of Higher Education and Research, Wardha, IND.
Cureus. 2024 Jul 30;16(7):e65750. doi: 10.7759/cureus.65750. eCollection 2024 Jul.
As systemic therapies, alongside radiation, for cancer treatment continue to evolve, the radiation oncology community is facing an increasing number of reirradiation (re-RT) of tumor sites subject to recurrences. There are multiple factors associated with choosing re-RT as a treatment option for a previously irradiated site. The factors include the site of previous radiotherapy (RT), the current extent of the disease, the nature of recurrence, the technique used for previous irradiation, and the previous RT details including dose and dose fractionation. There is a persistent heterogeneity in the workflow and decision-making in cancer care centers worldwide. The current review is an attempt to dive into the practices of decision-making for re-RT, interdisciplinary attention given to the re-RT patients, and acceptable doses to the organ at risk (OAR) deduced from the understanding of previous RT and radiobiology of the tumor and sites evidence of better techniques for effective execution.
随着癌症治疗的全身疗法与放射疗法不断发展,放射肿瘤学界面临着越来越多对复发肿瘤部位进行再照射(re-RT)的情况。选择再照射作为先前接受过照射部位的治疗方案存在多种相关因素。这些因素包括先前放疗(RT)的部位、当前疾病的范围、复发的性质、先前照射所采用的技术,以及先前放疗的详细情况,包括剂量和剂量分割。全球癌症护理中心在工作流程和决策方面一直存在异质性。本综述旨在深入探讨再照射的决策实践、给予再照射患者的跨学科关注,以及根据对先前放疗和肿瘤放射生物学的理解推导出的对危及器官(OAR)的可接受剂量,还有有效实施更好技术的证据。